Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
59
datasets available to search
ShareScore release 0.9.0
Dataset results
59 results for “Tigecycline”
French Study In ICU Patients Treated With Tigecycline
ClinicalTrials.gov study NCT00799591. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age
ClinicalTrials.gov study NCT00488345. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
ClinicalTrials.gov study NCT00195351. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects
ClinicalTrials.gov study NCT01560143. IPD Sharing: NO. Countries: 1. Publications: 1.
Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections
ClinicalTrials.gov study NCT00368537. IPD Sharing: Not stated. Countries: 12. Publications: 1.
A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
ClinicalTrials.gov study NCT01721408. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia
ClinicalTrials.gov study NCT00707239. IPD Sharing: Not stated. Countries: 14. Publications: 1.
Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Ost
ClinicalTrials.gov study NCT00366249. IPD Sharing: Not stated. Countries: 39. Publications: 1.
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
ClinicalTrials.gov study NCT00230971. IPD Sharing: Not stated. Countries: 19. Publications: 1.
Data from: Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae: A retrospective cohort study
<p><strong>Purpose:</strong> Infection by carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKP) has high mortality. There is no clear optimal therapeutic choice for pneumonia caused by CRKP. The aim of this study was to compare the clinical outcomes and safety of the standard doses of polymyxin B-based regimens vs tigecycline-based regimens and to identify risk factors for mortality.</p> <p><strong>Methods:</strong><strong> </strong>This retrospective cohort study included patients with pneumonia caused by CRKP for three years. The primary outcomes were 7-day bacterial eradication rate and 14- and 28-day all-cause mortality. The secondary outcome was incidence of acute kidney injury.</p> <p><strong>Results:</strong><strong> </strong>Seventy-three patients were included in this study, 29 in the<strong> </strong>polymyxin B-based combination therapy group and 44 in tigecycline-based combination therapy group. There were no significant differences between the two groups in terms of the 7-day bacterial eradication rate (31.0% vs 20.5%, <em>P</em>=0.409), the 14-day all-cause mortality (37.9% vs 22.7%, <em>P</em>=0.160), and the incidence of acute kidney injury (14.3% vs 6.8%, <em>P</em>=0.526). The 28-day all-cause mortality in the polymyxin B-based therapy group was higher than in the tigecycline-based group (75.9% vs 45.5%, <em>P</em>=0.010). Binary logistic regression analysis revealed that male and previous use of carbapenems were independent factors associated with 28-day all-cause mortality for patients treated with polymyxin B (<em>P</em><0.05).</p> <p><strong>Conclusions:</strong><strong> </strong>Polymyxin B-based combination therapy at the standard dose should be used with caution for patients with CRKP-induced pneumonia, especially for men who used carbapenems prior to CRKP detection.</p>
Tigecycline among clinically significant multidrug resistant pathogens
<p><span><strong>Purpose</strong>:</span> Tigecycline, a glycylcycline antibiotic is a promising option for the treatment of single or multidrug-resistant pathogens. The aim of the study was to evaluate the in-vitro Tigecycline susceptibility of various pathogens from clinical samples received at tertiary care hospitals in South India. </p> <p><span><strong>Methods</strong>:</span> The analysis of specimens from patients admitted was carried out in this retrospective cross-sectional study. The identification and antimicrobial susceptibility testing were performed by semi-automated Vitek 2 systems and Kirby Bauer method. The pattern of data analysis was done by descriptive statistics.</p> <p><span><strong>Results</strong>:</span> Among 2,574 isolates, 812 isolates were gram-positive pathogens and 1762 isolates were gram-negative pathogens. Resistance to Tigecycline was more common among gram-negative pathogens (18.62%) in comparison to the gram-positive pathogens (0.49%). Among 740 Extended Spectrum Beta Lactamases (ESBL) producers such as <em>Klebsiella</em> species & <em>E</em>. <em>coli</em>, 629 isolates were susceptible, and 93 isolates were resistant to the tigecycline. All the Methicillin Resistant <em>Staphylococcus</em> <em>aureus</em> (MRSA) isolates were susceptible to tigecycline. Tigecycline was found to be highly effective in vitro for elimination of infections caused by both gram-positive and gram-negative pathogens.</p> <p><span><strong>Conclusion</strong>:</span> Multidrug-resistant (MDR) pathogens like <em>Acinetobacter</em> species and <em>Klebsiella</em> species are highly susceptible to Tigecycline, and it remains one of the key drugs in monotherapy & combination therapy. All MRSA were sensitive to tigeclycline. The use of combination therapy becomes crucial to prevent the development of Pan Drug resistance.</p>
Tigecycline for Treatment of Rapidly Growing Mycobacteria
ClinicalTrials.gov study NCT00600600. IPD Sharing: NO. Countries: 1. Publications: 1.
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
ClinicalTrials.gov study NCT00080496. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections
ClinicalTrials.gov study NCT00136201. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Post-Authorization Study Evaluating Safety Of Tigecycline
ClinicalTrials.gov study NCT00827541. IPD Sharing: Not stated. Countries: 0. Publications: 3.
Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoni
ClinicalTrials.gov study NCT04489459. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone
ClinicalTrials.gov study NCT00376324. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects
ClinicalTrials.gov study NCT01287793. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.
ClinicalTrials.gov study NCT00205816. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock
ClinicalTrials.gov study NCT02191475. IPD Sharing: Not stated. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.